Reproductive outcomes after hydatiform mole and gestational trophoblastic neoplasia

References

• Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol 1978;131:665–71
   PubMed Web of Science ®Google Scholar
• Lurain JR. Gestational trophoblastic tumors. Semin Surg Oncol 1990;6:347–53
   PubMed Web of Science ®Google Scholar
• Shih IM, Kurman RJ. Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol 1998;22:1393–403
   PubMed Web of Science ®Google Scholar
• Feltmate CM, Genest DR, Goldstein DP, Berkowitz RS. Advances in the understanding of placental site trophoblastic tumor. J Reprod Med 2002;47:337–41
   PubMed Web of Science ®Google Scholar
• Sebire NJ, Lindsay I. Current issues in the histopathology of gestational trophoblastic tumors. Fetal Pediatr Pathol 2010;29:30–44
   PubMed Web of Science ®Google Scholar
• Savage PM, Sita-Lumsden A, Dickson S, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol 2013;33:406–11
   PubMedGoogle Scholar
• Seckl MJ, Fisher RA, Salerno G, et al. Choriocarcinoma and partial hydatidiform moles. Lancet 2000;35636–9
   Google Scholar
• Feltmate CM, Batorfi J, Fulop V, et al. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet Gynecol 2003;101:732–6
   PubMed Web of Science ®Google Scholar
• Kerkmeijer L, Wielsma S, Bekkers R, et al. Guidelines following hydatidiform mole: a reappraisal. Aust N Z J Obstet Gynaecol 2006;46:112–18
   PubMed Web of Science ®Google Scholar
• Golfier F, Raudrant D, Frappart L, et al. First epidemiological data from the French Trophoblastic Disease Reference Center. Am J Obstet Gynecol 2007;196:172–5
   PubMedGoogle Scholar
• Schmitt C, Doret M, Massardier J, et al. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type. Gynecol Oncol 2013;130:86–9
   PubMed Web of Science ®Google Scholar
• Ngan HY, Bender H, Benedet JL, et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet 2003;83:175–7
   PubMed Web of Science ®Google Scholar
• Lybol C, Sweep FC, Ottevanger PB, et al. Linear regression of postevacuation serum human chorionic gonadotropin concentrations predicts postmolargestational trophoblastic neoplasia. Int J Gynecol Cancer 2013;23:1150–6
   PubMed Web of Science ®Google Scholar
• Kani KK, Lee JH, Dighe M, et al. Gestational trophoblastic disease: multimodality imaging assessment with special emphasis on spectrum of abnormalities and value of imaging in staging and management of disease. Curr Probl Diagn Radiol 2012;41:1–10
   PubMedGoogle Scholar
• Mapelli P, Mangili G, Picchio M, et al. Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. Eur J Nucl Med Mol Imaging 2013;40:505–13
   PubMed Web of Science ®Google Scholar
• Kohorn EI. Imaging practices in the diagnosis and management of gestational trophoblastic disease: an assessment. J Reprod Med 2012;57:207–10
   PubMed Web of Science ®Google Scholar
• Wolfberg AJ, Feltmate C, Goldstein DP, et al. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy. Obstet Gynecol 2004;104:551–4
   PubMed Web of Science ®Google Scholar
• Wolfberg AJ, Growdon WB, Feltmate CM, et al. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy. Obstet Gynecol 2006;108:393–6
   PubMed Web of Science ®Google Scholar
• Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997;15:2636–43
   PubMed Web of Science ®Google Scholar
• McNeish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002;20:1838–44
   PubMed Web of Science ®Google Scholar
• El-Helw LM, Hancock BW. Treatment of metastatic gestational trophoblastic neoplasia. Lancet Oncol 2007;8:715–24
   PubMed Web of Science ®Google Scholar
• Cagayan MS. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. J Reprod Med 2012;57:231–6
   PubMed Web of Science ®Google Scholar
• Deng L, Zhang J, Wu T, Lawrie TA. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev 2013;1:CD005196
   PubMedGoogle Scholar
• Willemse PH, Aalders JG, Bouma J, Sleijfer DT. Chemotherapy-resistant gestational trophoblastic neoplasia treated successfully with cisplatin, etoposide, and bleomycin. Obstet Gynecol 1988;71:438–40
   PubMed Web of Science ®Google Scholar
• Azab M, Droz JP, Theodore C, et al. Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors. Cancer 1989;64:1829–32
   PubMed Web of Science ®Google Scholar
• Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/c yclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000;18:854–9
   PubMed Web of Science ®Google Scholar
• Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol 2005;97:618–23
   PubMed Web of Science ®Google Scholar
• Even C, Pautier P, Duvillard P, et al. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia. Eur J Cancer 2014;50:2082–9
   PubMed Web of Science ®Google Scholar
• Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 2013;31:280–6
   PubMed Web of Science ®Google Scholar
• Benigno BB. High-dose chemotherapy with autologous stem cell support as salvage therapy in recurrent gestational trophoblastic disease. Int J Gynecol Cancer 2013;23:1331–3
   PubMed Web of Science ®Google Scholar
• Kohorn EI. Worldwide survey of the results of treating gestational trophoblastic disease. J Reprod Med 2014;59:145–53
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Newlands ES, Lutz JM, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996;14:2769–73
   PubMed Web of Science ®Google Scholar
• Potzsch C, Fetscher S, Mertelsmann R, Lubbert M. Acute myelomonocytic leukemia secondary to synchronous carcinomas of the breast and lung, and to metachronous renal cell carcinoma. J Cancer Res Clin Oncol 1997;123:678–80
   PubMed Web of Science ®Google Scholar
• Shearer P, Kapoor G, Beckwith JB, et al. Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group. J Pediatr Hematol Oncol 2001;23:109–11
   PubMed Web of Science ®Google Scholar
• Domer PH, Head DR, Renganathan N, et al. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 1995;9:1305–12
   PubMed Web of Science ®Google Scholar
• Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 2012;9:2444–53
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998;16:3386–91
   PubMed Web of Science ®Google Scholar
• Sandoval C, Pui CH, Bowman LC, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 1993;11:1039–45
   PubMed Web of Science ®Google Scholar
• Gudipudi DK, Hartzfeld K, Montemarano N, Del Priore G. Decreased breast cancer rates among women with choriocarcinoma. Gynecol Oncol 2008;110:202–5
   PubMed Web of Science ®Google Scholar
• Russo IH, Koszalka M, Gimotty PA, Russo J. Protective effect of chorionic gonadotropin on DMBA-induced mammary carcinogenesis. Br J Cancer 1990;62:243–7
   PubMed Web of Science ®Google Scholar
• Russo IH, Russo J. Hormonal approach to breast cancer prevention. J Cell Biochem 2000;34:1–6
   Google Scholar
• Sisti G, Kanninen TT, Asciutti S, et al. Rate of second primary tumors following diagnosed choriocarcinoma: a SEER analysis (1973–2010). Gynecol Oncol 2014;134:90–5
   PubMed Web of Science ®Google Scholar
• Kohn LD, Shimura H, Shimura Y, et al. The thyrotropin receptor. Vitam Horm 1995;50:287–384
   PubMedGoogle Scholar
• Hershman JM. Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid. Best Pract Res Clin Endocrinol Metab 2004;18:249–65
   PubMed Web of Science ®Google Scholar
• Matsui H, Iitsuka Y, Suzuka K, et al. Subsequent pregnancy outcome in patients with spontaneous resolution of HCG after evacuation of hydatidiform mole: comparison between complete and partial mole. Hum Reprod 2001;16:1274–7
   PubMed Web of Science ®Google Scholar
• Lorigan PC, Sharma S, Bright N, et al. Characteristics of women with recurrent molar pregnancies. Gynecol Oncol 2000;78:288–92
   PubMed Web of Science ®Google Scholar
• Kim JH, Park DC, Bae SN, et al. Subsequent reproductive experience after treatment for gestational trophoblastic disease. Gynecol Oncol 1998;71:108–12
   PubMed Web of Science ®Google Scholar
• Sebire NJ, Fisher RA, Foskett M, et al. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG 2003;110:22–6
   PubMed Web of Science ®Google Scholar
• Vargas R, Barroilhet LM, Esselen K, et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 2014;59:188–94
   PubMed Web of Science ®Google Scholar
• Peigné M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol 2014;12:26
   PubMed Web of Science ®Google Scholar
• Dunlop CE, Anderson RA. Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women. Maturitas 2015;80:245–50
   PubMed Web of Science ®Google Scholar
• Iwase A, Sugita A, Hirokawa W, et al. Anti-Müllerian hormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia. Eur J Obstet Gynecol Reprod Biol 2013;167:194–8
   PubMed Web of Science ®Google Scholar
• Wong JM, Liu D, Lurain JR. Reproductive outcomes after multiagent chemotherapy for high-risk gestational trophoblastic neoplasia. J Reprod Med 2014;59:204–8
   PubMed Web of Science ®Google Scholar
• Bower M, Rustin GJ, Newlands ES, et al. Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years. Eur J Cancer 1998;34:1204–7
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Booth M, Dent J, et al. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J 1984;288:103–6
   PubMed Web of Science ®Google Scholar
• Woolas RP, Bower M, Newlands ES, et al. Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J Obstet Gynaecol 1998;105:1032–5
   PubMedGoogle Scholar
• Matsui H, Iitsuka Y, Suzuka K, et al. Risk of abnormal pregnancy completing chemotherapy for gestational trophoblastic tumor. Gynecol Oncol 2003;88:104–7
   PubMed Web of Science ®Google Scholar
• Chang Y-L, Chang T-C, Hsueh S, Huang K-G. Prognostic factors and treatment for placental site trophoblastic tumor – report of 3 cases and analysis of 88 cases. Gynecol Oncol 1999;73:216–22
   PubMed Web of Science ®Google Scholar
• Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol 2005;99:603–7
   PubMed Web of Science ®Google Scholar
• Baergen RN, Rutgers JL, Young RH, et al. Placental site trophoblastic tumor: a study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 2006;100:511–20
   PubMed Web of Science ®Google Scholar
• Bouquet de la Jolinière J, Khomsi F, Fadhlaoui A, et al. Placental site trophoblastic tumor: a case report and review of the literature. Front Surg 2014;1:31
   Google Scholar
• Feltmate CM, Genest DR, Wise L, et al. Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center. Gynecol Oncol 2001;82:415–19
   PubMed Web of Science ®Google Scholar
• Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet 2009;374:48–55
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Tsubamoto H, Hori M, et al. Case of PSTT treated with chemotherapy followed by open uterine tumor resection to preserve fertility. Gynecol Oncol 2002;87:303–7
   PubMed Web of Science ®Google Scholar
• Pfeffer PE, Sebire N, Lindsay I, et al. Fertility-sparing partial hysterectomy for placental-site trophoblastic tumour. Lancet Oncol 2007;8:744–6
   PubMed Web of Science ®Google Scholar
• Shen X, Xiang Y, Guo L, et al. Fertility-preserving treatment in young patients with placental site trophoblastic tumors. Int J Gynecol Cancer 2012;22:869–74
   PubMed Web of Science ®Google Scholar
• Tse KY, Ngan HY. Gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 2012;26:357–70
   PubMed Web of Science ®Google Scholar
• Zhao J, Xiang Y, Guo L, et al. Reservation of fertility for seventeen patients with placental site trophoblastic tumor. Zhonghua Fu Chan Ke Za Zhi 2014;49:265–9
   PubMedGoogle Scholar